Posted by Michael Wonder on 21 Feb 2026
US FDA accepts Teva’s new drug application for olanzapine extended release injectable suspension (TEV-'749) for the once monthly treatment of schizophrenia in adults
20 February 2026 - Teva Pharmaceuticals and Medincell announced today that the US FDA has accepted its new drug application (NDA) for olanzapine extended release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults.
TEV-'749 is designed to improve real world treatment adherence and help patients maintain long-term stability, with the goal of addressing a critical treatment gap for people living with schizophrenia.
